
7 Steps to Prescribing Lecanemab for Alzheimer’s
Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.
Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.
Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer’s. New investment will enhance global medicine production, benefiting millions of patients worldwide
In a new Alzheimer’s study, Rexulti (brexpiprazole) significantly reduced agitation. Learn the kinds of agitation it reduced and by how much.
There are no approved treatments for DLB, though it is the second most common type of dementia. Do drugs like donepezil hold the key?
While the initial headlines might seem discouraging, there’s always more to the story. 🌟
The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?
VIDEO + ARTICLE: Kisunla (generic name: Donanemab) slowed cognitive and functional decline 35%. Once-monthly infusions reduced Alzheimer’s plaque 84%.
China is the third country to launch LEQEMBI for sale, to fight Alzheimer’s, following the United States and Japan.
Three FDA-Approved drugs, terazosin, doxazosin, and alfuzosin, have a happy side effect; they boost energy production in brain cells. New studies suggest this slows or prevents Dementia with Lewy Bodies.
Grandma hates taking her medications. With her dementia, she ends up asking 10 different times why she has to take it! What should I do?
Learn how a personalized Alzheimer’s Weekly Newsletter can boost donations in your not-for-profit dementia organization.
INNOVATION – VIDEO: A big supermarket launched a ‘relaxed’ checkout lane to make life a little less stressful for people with dementia and other vulnerable people.
VIDEO + ARTICLE: Residential areas with more green space were associated with faster thinking, better attention, and higher overall cognitive function in a federal study. Learn more.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.